Has IL2 a role in the management of minimal residual disease for acute leukemia?
Based on pre-clinical findings and on more recent preliminary in vivo data it has been suggested that immunotherapy with Interleukin 2 (IL2) may be employed in the treatment of acute leukemia patients. Here we shall discuss the biological and clinical observations which indicate that this innovative therapeutic approach may play a role in the management of minimal residual disease.
Foa
R
R
Dipartimento di Scienze Biomediche ed Oncologia Umana, Torino, Italy.
Meloni
G
G
Guarini
A
A
Mandelli
F
F
Gavosto
F
F
D000208:Acute Disease; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics / Q000627:therapeutic use*; D007938:Leukemia / Q000628:therapy*; D014162:Transfection
D007376:Interleukin-2